Oral tablet for moderate to severe plaque psoriasis
Treatments studied
Part of Skin clinical trials.
This study tests an experimental oral tablet (CMS-D001) to see if it can safely and effectively reduce the severity of moderate to severe plaque psoriasis. It may be an easier treatment option compared to injections or light therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 to 75 years
- Diagnosed with plaque psoriasis for at least 6 months
- Psoriasis covers at least 10% of your body surface area (about 10 palms)
- Psoriasis is moderate to severe and you are a candidate for light therapy or systemic treatment
- No other types of psoriasis (like guttate or pustular) in the past 3 months
- No active infections (like shingles, TB, hepatitis B/C, HIV) or recent serious infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine (HS-20137) for moderate-to-severe plaque psoriasis, a condition causing thick, scaly patches on the skin. It aims to see if this medicine can safely reduce the severity of psoriasis and improve quality of life.
This study tests an investigational medicine (HS-20118) for people with moderate-to-severe plaque psoriasis. The goal is to see if the drug can safely and effectively reduce psoriasis symptoms and improve quality of life.
This study tests an experimental once-daily tablet for adults with moderate-to-severe plaque psoriasis who haven't had enough relief from standard creams or light therapy. The goal is to see if it can clear skin more effectively than placebo.
This trial tests an experimental drug called ICP-488 for people with moderate to severe plaque psoriasis. It aims to see if the drug can improve symptoms and is safe, and may be an option if you need stronger treatment than creams or light therapy.
This trial tests an investigational drug, HB0017, in adults with moderate to severe plaque psoriasis. If you have had psoriasis for at least 6 months and have not used certain biologic treatments, you may be able to join.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
Hear when a new Moderate to Severe Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.